Nongnuch SirachainanPakawan WongwerawattanakoonDuantida SongdejAmpaiwan ChuansumritSurapong LertthammakiatFaculty of Medicine Ramathibodi Hospital, Mahidol University2022-08-042022-08-042021-04-01Journal of the Medical Association of Thailand. Vol.104, No.4 (2021), 672-675012522082-s2.0-85104634577https://repository.li.mahidol.ac.th/handle/123456789/78299The present case series described six chronic immune thrombocytopenia patients (cITP), with a median age of 7.7 (7.0 to 13.0) years and low platelet count at 15,500 (7,000 to 20,000)/uL. They were suffering from bleeding symptoms and side effects of treatment. After enrollment, they were treated with thrombopoietin receptor agonist (eltrombopag). Five patients responded positively, showing a median platelet count of 115,000 (39,000 to 433,000)/uL. The median dose of eltrombopag used was 1.3 (0.8 to 2.2) mg/kg/day. The quality of life (QoL) improved for all patients, with their median overall score using a Pediatric QoL questionnaire showing 25.0% improvement. Median scores also showed improvements in each sphere of life functioning as physical (30.8%), emotional (26.4%), social (16.4%), and school (21.4%). The present report demonstrated that a select group of cITP patients, with low platelet count and bleeding symptoms, benefitted from treatment with eltrombopag, as shown by increased platelet counts and improved QoL.Mahidol UniversityMedicineArticleSCOPUS10.35755/jmedassocthai.2021.04.11651